Post-vaccination Symptoms with Second Dose of AstraZeneca in a Sample of Immunized Population of Ecuadorian Public Servants

Since AstraZeneca is a new vaccine against SARSCOV2, it should be monitored worldwide. This study presents the adverse reactions caused by the second dose of the AstraZeneca vaccine. Thequantitative, descriptive, cross-sectional research used a validated survey conducted on 428 public staff who were vaccinated with the second dose of the ChAdOx1-S vaccine at the Escuela Superior Politécnica de Chimborazo, the results were processed in Jamovi. 289 respondents reported having symptoms after inoculation, women (13.15%) presented more symptoms than men (7.27%). Most of the symptoms, both local and systemic, were mild and subsided with the administration of oral analgesics and lasted up to three days in 50% of the cases. AstraZeneca’s vaccine proves to be a safe biologic vaccine to generate antibodies against SARSCOV” in the adult population, and its use is therefore recommended. Keywords: drug-related side effects and adverse reactions, coronavirus infections, pharmacovigilance Resumen Introducción: Dado que se trata de una nueva vacuna contra el SARSCOV2, debe ser monitoreada a nivel mundial, el presente estudio presenta las reacciones adversas presentadas con la segunda dosis de la vacuna AstraZeneca. Materiales y Métodos: La presente investigación cuantitativa, descriptiva, transversal, utilizó una encuesta validada aplicada a 428 funcionarios públicos que fueron vacunados con la segunda dosis de la vacuna ChAdOx1- S en la Escuela Superior Politécnica de Chimborazo, los resultados fueron procesados en Jamovi . Resultados: 289 encuestados informaron tener síntomas después de la inoculación, las mujeres (13,15%) presentaron más síntomas que los hombres (7,27%). La mayoría de los síntomas, tanto locales como sistémicos, fueron leves y cedieron con la administración de analgésicos orales y duraron hasta tres días en el 50% de los casos. Conclusiones: La vacuna de AstraZeneca demuestra ser una vacuna biológica segura para generar anticuerpos frente al SARSCOV” en la población adulta, por lo que se recomienda su uso. Palabras Clave: kwd2

Post-vaccination Symptoms with Second Dose of AstraZeneca in a Sample of Immunized Population of Ecuadorian Public Servants

Abstract Since AstraZeneca is a new vaccine against SARSCOV2, it should be monitored worldwide. This study presents the adverse reactions caused by the second dose of the AstraZeneca vaccine. Thequantitative, descriptive, cross-sectional research used a validated survey conducted on 428 public staff who were vaccinated with the second dose of the ChAdOx1-S vaccine at the Escuela Superior Politécnica de Chimborazo, the results were processed in Jamovi. 289 respondents reported having symptoms after inoculation, women (13.15%) presented more symptoms than men (7.27%). Most of the symptoms, both local and systemic, were mild and subsided with the administration of oral analgesics and lasted up to three days in 50% of the cases. AstraZeneca's vaccine proves to be a safe biologic vaccine to generate antibodies against SARSCOV" in the adult population, and its use is therefore recommended